| Biological Sciences | 2021-2025 | 48 | CN 15 | 99.96 |
| Medical and Health Sciences | 2021-2025 | 213 | CN 21 | 99.96 |
| Cancer Research | Lifetime | 311 | CN 22 | 98.14 |
| Complementary and Alternative Medicine | Lifetime | 493 | CN 44 | 96.78 |
| Pharmacology | Lifetime | 943 | CN 84 | 77.25 |
| Molecular Biology | 2021-2025 | 47 | CN 23 | 99.81 |
| Cancer Research | 2021-2025 | 11 | CN 5 | 99.62 |
| Immunology | 2021-2025 | 38 | CN 7 | 99.19 |
| Complementary and Alternative Medicine | 2021-2025 | 26 | CN 6 | 98.79 |
| Surgery | 2021-2025 | 196 | CN 14 | 98.84 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 156 | CN 21 | 98.89 |
| Oncology | 2021-2025 | 157 | CN 18 | 98.78 |
| Pathology and Forensic Medicine | 2021-2025 | 181 | CN 18 | 95.08 |
| Genetics | 2021-2025 | 277 | CN 20 | 92.80 |
| Biomedical Engineering | 2021-2025 | 836 | CN 456 | 94.36 |
| Medical Physiology | 2021-2025 | 598 | CN 37 | 90.77 |
| Nutrition and Dietetics | 2021-2025 | 256 | CN 83 | 91.15 |
| Pediatrics, Perinatology and Child Health | 2021-2025 | 438 | CN 20 | 89.54 |
| Neuroscience of Neurology | 2021-2025 | 229 | CN 30 | 87.04 |
| Urology | 2021-2025 | 107 | CN 5 | 88.10 |
| Rheumatology | 2021-2025 | 405 | CN 28 | 82.37 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 757 | CN 93 | 82.13 |
| Cell Biology | 2021-2025 | 206 | CN 23 | 79.69 |
| Cancer-related molecular mechanisms research | Lifetime | 154 | CN 62 | 99.29 |
| Ferroptosis and cancer prognosis | Lifetime | 88 | CN 32 | 98.54 |
| MicroRNA in disease regulation | Lifetime | 305 | CN 107 | 98.87 |
| Circular RNAs in diseases | Lifetime | 230 | CN 121 | 98.32 |
| RNA modifications and cancer | Lifetime | 865 | CN 111 | 98.41 |
| Nanoplatforms for cancer theranostics | Lifetime | 705 | CN 469 | 97.67 |
| Ginseng Biological Effects and Applications | Lifetime | 301 | CN 152 | 95.32 |
| Kruppel-like factors research | Lifetime | 301 | CN 33 | 94.46 |
| Traditional Chinese Medicine Analysis | Lifetime | 494 | CN 371 | 93.64 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 645 | CN 118 | 90.90 |
| Wnt/β-catenin signaling in development and cancer | Lifetime | 763 | CN 38 | 93.06 |
| Medicinal Plants and Bioactive Compounds | Lifetime | 612 | CN 197 | 79.39 |
| Cancer-related molecular mechanisms research | 2021-2025 | 22 | CN 15 | 99.72 |
| MicroRNA in disease regulation | 2021-2025 | 31 | CN 16 | 99.45 |
| Ferroptosis and cancer prognosis | 2021-2025 | 67 | CN 50 | 98.66 |
| Epigenetics and DNA Methylation | 2021-2025 | 98 | CN 45 | 97.78 |
| Immune Cell Function and Interaction | 2021-2025 | 143 | CN 32 | 97.81 |
| RNA modifications and cancer | 2021-2025 | 279 | CN 189 | 97.43 |
| Circular RNAs in diseases | 2021-2025 | 110 | CN 79 | 97.31 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 126 | CN 28 | 95.79 |
| Immunotherapy and Immune Responses | 2021-2025 | 385 | CN 106 | 95.20 |
| Hedgehog Signaling Pathway Studies | 2021-2025 | 28 | CN 3 | 91.04 |
| Extracellular vesicles in disease | 2021-2025 | 438 | CN 265 | 93.81 |
| Ubiquitin and proteasome pathways | 2021-2025 | 216 | CN 102 | 92.13 |
| Inflammasome and immune disorders | 2021-2025 | 225 | CN 113 | 92.37 |
| RNA regulation and disease | 2021-2025 | 126 | CN 38 | 89.58 |
| Virus-based gene therapy research | 2021-2025 | 339 | CN 80 | 92.19 |
| CAR-T cell therapy research | 2021-2025 | 914 | CN 96 | 94.88 |
| Ginseng Biological Effects and Applications | 2021-2025 | 97 | CN 84 | 91.49 |
| Kruppel-like factors research | 2021-2025 | 47 | CN 8 | 92.16 |
| Nanoplatforms for cancer theranostics | 2021-2025 | 952 | CN 808 | 94.78 |
| Cancer Mechanisms and Therapy | 2021-2025 | 171 | CN 67 | 90.22 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 636 | CN 279 | 89.20 |
| Vitamin K Research Studies | 2021-2025 | 28 | CN 5 | 86.56 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 236 | CN 19 | 88.51 |
| Urinary Bladder and Prostate Research | 2021-2025 | 354 | CN 23 | 91.50 |
| Eicosanoids and Hypertension Pharmacology | 2021-2025 | 103 | CN 18 | 86.36 |
| Prostate Cancer Treatment and Research | 2021-2025 | 981 | CN 47 | 91.98 |
| Cancer Research and Treatments | 2021-2025 | 421 | CN 181 | 86.04 |
| Genetic factors in colorectal cancer | 2021-2025 | 762 | CN 64 | 88.26 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 463 | CN 30 | 87.54 |
| Bladder and Urothelial Cancer Treatments | 2021-2025 | 928 | CN 117 | 90.32 |
| Immune Response and Inflammation | 2021-2025 | 444 | CN 192 | 83.64 |
| Spinal Cord Injury Research | 2021-2025 | 416 | CN 121 | 84.96 |
| Cancer-related gene regulation | 2021-2025 | 816 | CN 556 | 78.95 |
| Acupuncture Treatment Research Studies | 2021-2025 | 369 | CN 245 | 81.46 |
| Neurological Disease Mechanisms and Treatments | 2021-2025 | 658 | CN 263 | 77.60 |
| Hormonal and reproductive studies | 2021-2025 | 667 | CN 61 | 79.33 |
| Viral-associated cancers and disorders | 2021-2025 | 894 | CN 183 | 78.33 |
| Traditional Chinese Medicine Analysis | 2021-2025 | 449 | CN 400 | 76.02 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 493 | CN 109 | 70.70 |
| Galectins and Cancer Biology | 2021-2025 | 661 | CN 181 | 70.39 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 905 | CN 281 | 67.32 |
| Phagocytosis and Immune Regulation | 2021-2025 | 842 | CN 356 | 67.34 |
| Wnt/β-catenin signaling in development and cancer | 2021-2025 | 327 | CN 83 | 66.05 |
| Cholesterol and Lipid Metabolism | 2021-2025 | 492 | CN 109 | 63.92 |
| Nausea and vomiting management | 2021-2025 | 690 | CN 147 | 64.81 |
| Protein Tyrosine Phosphatases | 2021-2025 | 455 | CN 104 | 57.66 |
| Medicinal Plants and Bioactive Compounds | 2021-2025 | 467 | CN 204 | 54.39 |
| Histiocytic Disorders and Treatments | 2021-2025 | 459 | CN 73 | 53.16 |
| GDF15 and Related Biomarkers | 2021-2025 | 894 | CN 157 | 43.23 |